Author name: greenman

Mechanism, endpoints and why tesamorelin’s approval changes the evidentiary bar for the whole category.

Doses that moved endpoints, wound and cardiac repair data, and the safety margins that matter for protocol design.

A peptide encoded in mitochondrial DNA: AMPK activation, exercise-mimetic pathways, and endurance endpoints.

DAC vs no-DAC, pulse amplitude vs duration, and the baseline labs serious protocols run before either compound.

Three receptors, one molecule: where retatrutide’s trial data now stands, and how its potency curve is reshaping metabolic protocol design.

The immune peptide that is having a breakout year: the trial endpoints, the gut-barrier data, and what its unusual safety […]